THE EFFECTIVENESS OF EXPECTORANT HERBS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Main Article Content
Abstract
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airway inflammation, impaired mucociliary clearance, and excessive production of viscous bronchial secretions. These pathophysiological mechanisms contribute significantly to chronic cough, airflow limitation, and recurrent exacerbations, leading to a substantial decline in patients’ quality of life. Although conventional pharmacological therapy, including bronchodilators and mucolytics, remains the cornerstone of COPD management, long-term treatment may be associated with adverse effects, particularly in elderly patients with comorbidities. This has stimulated growing interest in complementary therapeutic approaches.
The present review analyzes current scientific evidence regarding the use of medicinal plants with expectorant, mucolytic, and anti-inflammatory properties as adjunctive therapy in COPD. Special attention is given to Glycyrrhiza glabra, Plantago major, Thymus vulgaris, and Tussilago farfara, which have been traditionally used in respiratory disorders and are supported by pharmacological and clinical data. The mechanisms of action, clinical relevance, and safety aspects of these phytotherapeutic agents are critically discussed. The available evidence suggests that rational integration of expectorant medicinal plants into standard COPD treatment regimens may contribute to symptom relief, improved sputum clearance, and enhanced quality of life, provided that safety considerations are carefully addressed.
Downloads
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Barnes PJ. Chronic Obstructive Pulmonary Disease: Pathogenesis and Treatment. London: Springer Nature, 2023.
2.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. Fontana (USA): GOLD Reports, 2024.
3.Ding Y, et al. Medicinal plants and compounds for chronic bronchitis treatment: efficacy and mechanisms. Phytomedicine. 2025;120:153789.
4.Ernst E, Pittler MH. Herbal Medicine: Evidence-Based Approaches. Edinburgh: Elsevier Health Sciences, 2022.
5.Wagner H, Ulrich-Merzenich G. Phytomedicine in Respiratory Diseases. Berlin: Springer-Verlag, 2021.
6.WHO. Monographs on Selected Medicinal Plants. Geneva: World Health Organization, 2022.
7.Shikov AN, Pozharitskaya ON. Medicinal Plants in Respiratory Diseases. Moscow: GEOTAR-Media, 2021.